Cytidine and Omega-3 Fatty Acids in Bipolar Disorder

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of the proposed clinical trial is to assess the effect of oral cytidine and omega-3 fatty acids (O3FA) on bipolar disorder symptoms. This study is a 4-month, randomized, parallel-group, double-blind, placebo-controlled pilot study of a combination of cytidine and omega-3 fatty acids in 90 recently ill subjects with bipolar disorder. During the 16 week period of the study, subjects are assigned to one of three groups: 1) omega-3 fatty acids + cytidine supplementation, 2) omega-3 fatty acids supplementation alone, and 3) placebo supplementation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mclean Hospital
• Collaborator: Stanley Medical Research Institute

Criteria

Inclusion Criteria:

• bipolar disorder

• mood episode within past year

• stable medication regimen

Exclusion Criteria:

• primary psychiatric disorder other than bipolar disorder

• significant suicide or homicide risk

• unstable medical conditions

• current or planned pregnancy

• lactose intolerance

• medications affecting lipid absorption or metabolism

• clozapine treatment